Taha Merghoub
Memorial Sloan Kettering Cancer Center
359 Papers
1K Citations
Taha Merghoub is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Immune system & Medicine. The author has an hindex of 67, co-authored 246 publications. Previous affiliations of Taha Merghoub include Columbia University & Ludwig Institute for Cancer Research.
Chat about Author
Papers
Systemic antitumor immunity by PD-1/PD-L1 inhibition is potentiated by vascular-targeted photodynamic therapy of primary tumors
Matthew J. O'Shaughnessy,Katie S. Murray,Stephen La Rosa,Sadna Budhu,Taha Merghoub,Alexander Somma,Sebastien Monette,Kwanghee Kim,Renato B. Corradi,Avigdor Scherz,Jonathan A. Coleman,Jonathan A. Coleman +11 more
TL;DR: A role for local immune modulation with VTP in combination with PD-1/PD-L1 pathway inhibition for generation of potent local and systemic antitumor responses is demonstrated.
Optimization of a self antigen for presentation of multiple epitopes in cancer immunity
José A. Guevara-Patiño,Manuel E. Engelhorn,Mary Jo Turk,Cailian Liu,Fei Duan,Gabrielle Rizzuto,Adam D. Cohen,Taha Merghoub,Jedd D. Wolchok,Alan N. Houghton +9 more
TL;DR: These studies demonstrate how rationally designed DNA vaccines directed against self antigens for enhanced antigen processing and presentation reveal novel self epitopes and elicit multi-specific T cell responses to nonimmunogenic, nonmutated self antIGens, enhancing immunity against cancer self antigelens.
Neoantigen quality predicts immunoediting in survivors of pancreatic cancer
Marta Łuksza,Zachary Sethna,Luis A. Rojas,Jayon Lihm,Barbara Bravi,Yuval Elhanati,Kevin C. Soares,Masataka Amisaki,Anton Dobrin,David Hoyos,Pablo Guasp,Abderezak Zebboudj,Rebecca Yu,A. Chandra,Tracey A. Waters,Zagaa Odgerel,Joanne P. Leung,Rajya Kappagantula,Alvin Makohon-Moore,Amber L. Johns,A. Gill,Mathieu Gigoux,Jedd D. Wolchok,Taha Merghoub,Michel Sadelain,Erin V Patterson,Rémi Monasson,Thierry Mora,Aleksandra M. Walczak,Simona Cocco,Christine A. Iacobuzio-Donahue,Benjamin Greenbaum,Vinod P. Balachandran +32 more
TL;DR: In this article , the authors investigate how 70 human pancreatic cancers evolved over 10 years and find that rare long-term survivors of pancreatic cancer who have stronger T cell activity in primary tumours develop genetically less heterogeneous recurrent tumours with fewer immunogenic mutations (neoantigens).
An MHC-restricted antibody-based chimeric antigen receptor requires TCR-like affinity to maintain antigen specificity
Marcela V. Maus,Jason Plotkin,Gopinadh Jakka,Guillaume Stewart-Jones,Isabelle Riviere,Taha Merghoub,Jedd D. Wolchok,Christoph Renner,Christoph Renner,Michel Sadelain,Michel Sadelain +10 more
TL;DR: It is found that despite the specificity of the soluble Fab, the same antibody in the form of a CAR caused moderate lysis of HLA-A2 expressing targets independent of antigen owing to T cell avidity, and there is exciting potential for CARs to expand their repertoire to include a broad range of intracellular antigens.
Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade
Tavi Nathanson,Arun Ahuja,Alex Rubinsteyn,Bulent Arman Aksoy,Matthew D. Hellmann,Diana Miao,Eliezer M. Van Allen,Taha Merghoub,Jedd D. Wolchok,Alexandra Snyder,Jeff Hammerbacher +10 more
TL;DR: Cancer exome data obtained from a previously published study of 64 melanoma patients treated with CTLA-4 blockade and a new dataset of RNA-Seq data from 24 of those patients are reanalyzed and it is found that the predictive accuracy does not increase as analysis narrows from somatic mutation burden to predicted MHC Class I neoantigens, expressed neoantIGens, or homology to pathogens.
86